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Introduction
Obesity is a known risk factor for type 2 diabetes mellitus (T2DM). T2DM conveys increased risk for the 
development of  cardiovascular disease (CVD). In fact, diabetes mellitus is considered a “risk equivalent” 
of  established CVD itself  (1). Obese people with visceral, rather than subcutaneous, adiposity are at greater 
risk for the development of  T2DM and incident CVD. In the setting of  chronic caloric excess, an inflamma-
tory response is initiated in visceral adipose tissue (VAT) (2). The stimulus for this inflammatory response 
remains unknown. VAT inflammation results in adipocyte dysfunction, including failure to store free fatty 
acids as triglyceride and increased lipolysis. Excess free fatty acids are released into the circulation and 
deposited in ectopic tissues, such as the liver, skeletal muscle, heart, and pancreas. Ectopic lipid storage 
results in insulin resistance in target organs (2, 3). This paradigm has dominated our understanding of  
T2DM since the 1990s (4, 5). It follows that antiinflammatory therapies would be beneficial in the treat-
ment of  T2DM and the prevention of  CVD, yet the success of  antiinflammatory therapies in the treatment 
of  cardiometabolic disorders has been limited (6).
The ability of  VAT to stimulate this cycle of  inflammation and insulin resistance is underscored by the 
syndrome of  “normal-weight” obesity: patients with normal BMIs but increased waist circumference and 
disproportionately increased VAT (7). Despite having a normal BMI these patients are prone to insulin 
resistance and T2DM because of  excess VAT. These observations have led to interest in the direct adverse 
effects of  VAT on neighboring organs. For example, epicardial adipose tissue (EAT) is the visceral fat depot 
of  the heart (8). Modest amounts of  EAT are present in normal-weight humans; in overweight humans the 
amount of  EAT increases proportionately with obesity and VAT (9). EAT is contained within the visceral 
pericardium and supports the epicardial coronary arteries and great cardiac veins (8). Early studies by 
Mazurek et al. demonstrated that EAT surrounding atherosclerotic coronary arteries had increased expres-
Epicardial adipose tissue (EAT) is the visceral fat depot of the heart. Inflammation of EAT is 
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samples of EAT and subcutaneous adipose tissue (SAT) were obtained. Transcriptomic analysis 
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Immunohistochemistry showed more macrophages in EAT than SAT, but there was no difference 
in their number or activation state between groups. In contrast to prior studies, we did not find 
increased inflammatory gene expression in the EAT of patients with CAD. We conclude that the 
specific adipose tissue depot, rather than CAD status, is responsible for the majority of differential 
gene expression.
2insight.jci.org   https://doi.org/10.1172/jci.insight.124859
R E S E A R C H  A R T I C L E
3insight.jci.org   https://doi.org/10.1172/jci.insight.124859
R E S E A R C H  A R T I C L E
sion of  inflammatory genes and dense inflammatory cell infiltrates compared with subcutaneous adipose 
tissue (SAT) (10). This observation suggested that inflammation of  EAT may contribute to or exacerbate 
atherosclerosis in the underlying coronary artery. Many other groups have replicated these results, find-
ing increased inflammatory gene expression in the EAT of  patients with coronary artery disease (CAD) 
(11–14). However, there are some limitations to these prior studies. First, control patients without CAD 
were not routinely included. This is important because inflammation in VAT is typically greater than SAT 
even in normal conditions (15). Second, it impossible to discern the temporal relationship between the 
development of  CAD and inflammation in adjacent EAT. Therefore, to address some of  these limitations, 
we chose to directly compare gene expression in the EAT of  patients with and without CAD.
We hypothesized that inflammatory gene expression would be greater in the EAT of  patients with 
CAD. Contrary to our hypothesis, we found a greater number of  genes differentially expressed in the 
EAT of  patients without CAD. In particular, we found increased expression of  all 3 members of  the 
NR4A subfamily of  orphan nuclear hormone receptors (NR4A1, NR4A2, NR4A3) in the EAT of  those 
without CAD. Members of  this subfamily have been found to suppress inflammatory gene expression 
(16, 17). For example, whole-body and macrophage-specific deletion of  Nr4a1 in mice results in a wors-
ening of  atherosclerosis (17, 18). Therefore, we conclude that the development of  CAD may be asso-
ciated with decreased antiinflammatory gene expression in EAT. Promotion of  antiinflammatory effects 
via pharmacological activation of  the orphan nuclear hormone receptors may be advantageous in the 
treatment of  CAD and other cardiometabolic disorders and will be the focus of  future studies.
Results
Clinical characteristics. The clinical characteristics of  subjects are shown in Table 1. There was no difference in 
age, gender, BMI, comorbid conditions, or pertinent medication use. The mean age of  controls was 67.1 ± 
9.9 years and cases 65.3 ± 13.0 years (P = 0.70). There was a trend toward more female patients in the control 
group (46% vs. 23% for cases, P = 0.41). The mean Gensini score was 0.7 ± 1.3 in controls and 53.7 ± 27.2 in 
cases (P < 0.001). Therefore, with the exception of  the presence of  CAD, our study groups were well matched.
EAT contains smaller adipocytes and is more vascularized. We first compared the histological characteristics of  
SAT and EAT. Both SAT and EAT contained unilocular white adipocytes (Figure 1); no brown adipocytes 
were visualized. Control SAT adipocytes were significantly larger than those in EAT (5213 ± 1024 μm2 vs. 
3904 ± 1241 μm2, P < 0.01) (Figure 1). This relationship was also seen in cases (5136 ± 1058 μm2 vs. 3920 ± 
612 μm2, P < 0.01). There was no difference between cases and controls in depot-specific adipocyte size. We 
then used an endothelial-specific antibody (von Willebrand factor) to compare the number of  blood vessels in 
SAT and EAT (Figure 1). EAT had a greater number of  blood vessels than SAT; this was true for cases (2.2 ± 
1.67 vs. 0.66 ± 0.58 per HPF, P < 0.01) and controls (2.2 ± 1.29 vs. 0.89 ± 0.72 per HPF, P < 0.01). There was 
no difference between cases and controls in depot-specific blood vessel number.
Microarray analysis demonstrates predominantly depot-specific differences in gene expression. We then compared 
gene expression in SAT and EAT in control patients. Despite the absence of  significant CAD, there were 
large differences in gene expression between SAT and EAT (Figure 2 and Supplemental Table 1; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.124859DS1). In 
total, 693 genes were differentially expressed (FC > 1.5; P < 0.05). Expression of  383 genes was increased 
in EAT and 310 were increased in SAT. We then performed gene set enrichment analysis (GSEA) of  differ-
entially expressed genes in both depots. SAT was enriched for expression of  genes encoding proteins related 
to the renin-angiotensin system, neuroactive receptor-ligand interactions, and many biochemical pathways 
(insulin signaling, starch, sucrose, and butanoate metabolism) (Figure 2C). In contrast, EAT was enriched 
for expression of  genes encoding inflammatory pathways, such as complement and coagulation cascades, 
focal adhesion, and cytokine-receptor interaction (Figure 2C).
In patients with CAD 805 genes were differentially expressed between SAT and EAT (Figure 3 and 
Supplemental Table 1). Expression of  427 was increased in EAT and 328 in SAT. GSEA demonstrated that 
SAT was enriched for expression of  genes encoding proteins implicated in the renin-angiotensin system, 
nicotinate and nicotinamide metabolism, and TGF-β signaling pathways (Figure 3C). Similar to control 
patients, EAT was enriched for expression of  genes encoding proteins belonging to complement and coag-
ulation cascades, cell adhesion molecules, focal adhesion and calcium signaling pathways (Figure 3C).
We then directly compared the gene expression profile of EAT in cases and controls (Figure 4). Three 
hundred twenty-six genes were differentially regulated (1.5-fold change, P < 0.01). Expression of 312 genes 
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was increased in controls and 14 in cases (Figure 4A, Table 1, and Supplemental Table 1). Because of the 
small number of genes differentially regulated in the EAT of cases, no Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway was significantly enriched in this depot (Figure 4C). However, several pathways 
were increased in the EAT of controls, including olfactory transduction, pentose and glucuronate interconver-
sion, and Toll-like receptor transduction (Figure 4C).
We then compared gene expression in SAT between cases and controls (Figure 5). Expression of  218 
genes was significantly different; expression of  82 was increased in the SAT of  controls and 136 in the SAT 
of  cases (Figure 5A). No pathways were significantly enriched in the SAT of  controls; several pathways 
were increased in the SAT of  cases, including those encoding proteins implicated in circadian rhythms, 
chemokine signaling, and NOD receptor signaling (Figure 5C).
Finally, an advantage of the Human Gene 1.0 array is that it contains probes for MIRs. Therefore, we used 
this feature to compare MIR expression in SAT and EAT in cases and controls (Table 2 and Table 3). Expression 
of MIRs 126 and 1247 was significantly upregulated in the EAT of controls and cases compared with respective 
SAT. MIR24-2 expression was increased in the SAT of cases and controls in comparison with EAT.
Therefore, contrary to our expectations, microarray analysis did not demonstrate greater inflammatory 
gene expression in the EAT of  cases in comparison to controls. Rather, depot-specific differences predom-
inated, with SAT of  both cases and controls enriched in certain pathways (renin-angiotensin system, focal 
adhesion) and EAT of  both cases and controls enriched in others (complement and coagulation, calcium 
signaling) (Figure 2 and Figure 3).
Quantitative reverse transcription PCR and immunohistochemistry show that there is no difference in inflamma-
tion between EAT of  cases and controls. We performed quantitative reverse transcription (qRT-PCR) to verify 
the expression patterns that we observed in the microarray experiments. First, we showed that our samples 
displayed a depot-specific identity. EAT of  both cases and controls had a higher expression of  the visceral 
fat marker omentin-1 (INTLN1) (Figure 6A). In contrast, the SAT of  cases and controls expressed higher 
levels of  the subcutaneous fat marker neuronatin (NNAT) (Figure 6B). Expression of  common inflamma-
tory genes (CCR2, CCL2, IL8, IL6, PAI1, and TNFA) was not significantly different between groups (Figure 
6). Interestingly, expression of  3 members of  the orphan nuclear hormone receptor family was increased in 
the EAT of  control patients in comparison with cases (Figure 6, C–E).
We then performed immunohistochemistry for markers of classical (M1) and alternative (M2) macrophage 
activation. In both cases and controls, EAT had a significantly greater number of classical (CD11c+) and alterna-
Table 1. Clinical characteristics of study participants
Controls (n = 13) Cases (n = 13) P value
Age 67.1 ± 9.9 65.3 ± 13.0 0.70
Female 6 (46%) 3(23%) 0.41
BMI (kg/m2) 31.75 ± 5.7 29.5 ± 6.3 0.37
Hypertension 9 (69.2%) 9 (69.2%) 0.99
CHF 6 (46.1%) 4 (30.7%) 0.68
Diabetes mellitus 3 (23.0%) 4 (30.7%) 0.99
COPD 0 (0%) 2 (15.4%) 0.48
Chronic kidney disease 1 (7.7%) 2 (15.4%) 0.99
Hyperlipidemia 9 (69.2%) 10 (76.9%) 0.99
Obese 7 (53.8%) 4 (30.8%) 0.41
Gensini score 0.7 ± 1.3 53.7 ± 27.2 <0.001
Statins 6 (46%) 7 (53%) 0.99
Ejection fraction (%) 54.8 ± 18.1 53.22 ± 16.3 0.82
HbA1c% 6.0 ± 0.8 6.3 ± 0.9 0.48
TC (mg/dL) 179.3 ± 54.6 153.4 ± 47.6 0.31
LDL (mg/dL) 108.0 ± 41.9 88.8 ± 33.3 0.28
HDL (mg/dL) 45.7 ± 15.0 41.6 ± 13.5 0.54
TG (mg/dL) 119.6 ± 42.3 115.1 ± 6.0 0.86
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HbA1c%, hemoglobin A1c; TC, total 
cholesterol; LDL, low-density lipoprotein–cholesterol; HDL, high-density lipoprotein–cholesterol; TG, triglycerides.
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tive (mannose receptor C-type 1–positive [MRC1+]) macrophages than SAT (Figure 7). There was no difference 
in the number of positive-stained cells between the EAT of cases and controls (Figure 7). Furthermore, we did 
not observe a difference in the ratio of M1/M2 cells per depot or on a disease-specific basis (Figure 7E).
Discussion
There has been much recent interest in the potential role of EAT as a direct link between obesity and CAD (19, 
20). Initial studies showed that EAT had greater mRNA and protein expression of inflammatory genes and 
clusters of inflammatory cells (10, 21). Subsequent analyses have demonstrated that EAT tends to have a more 
inflammatory gene expression profile than SAT, and this is true even in the absence of CAD (12–14). The major-
ity of the data suggest that EAT is very similar to abdominal VAT in that it tends to be more immunologically 
active than SAT even in normal conditions. There may be an additional increase in inflammation in the setting 
of atherosclerosis, but it is the adipose organ itself, not the disease state, that dictates the majority of differences 
in gene expression (13, 14). This concept was originally proposed by Chatterjee et al. in 2009 (22).
Our study confirms many of  these findings and makes several potentially novel observations. First, 
we confirmed that type of  adipose tissue, rather than the disease condition, is responsible for most of  the 
differences in gene expression. Six hundred ninety-three genes were differentially expressed between SAT 
and EAT in controls and 805 in cases. In particular, there is a hallmark panel of  genes whose expression 
is consistently increased in EAT (INTLN1, SYT4, CFB, ESR, INMT, PRG4, and ALOX15) compared with 
SAT irrespective of  the presence or absence of  CAD (13). In contrast, when directly comparing the EAT of  
cases and controls, there are fewer differences in gene expression (326 probes different). However, among 
Figure 1. EAT contains smaller adipocytes and greater number of blood vessels. (A) Adipocyte size was determined using Adiposoft software on H&E-
stained sections of SAT and EAT in both cases and controls (top right). The mean adipocyte size in SAT was larger than those in EAT (top left). This was 
true for both cases and controls. (**P < 0.01 SAT vs. EAT, 2-tailed Student’s t test; n = 13 per group. In each column, individual subjects are plotted, and 
error bars show the mean and standard deviation per group). (B) Sections of SAT and EAT were stained with vWF, and the number of blood vessels per 
high-power field (HPF) was quantified (bottom right). EAT had more blood vessels per field than SAT. (*P < 0.05 EAT vs. SAT, 2-tailed Student’s t test; n = 
13 per group. In each column, individual subjects are plotted, and error bars show the mean and standard deviation per group).
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Figure 2. Comparison of gene expression between SAT and EAT in controls. (A) Volcano plot of 693 probes that were differentially expressed at a level 
of 1.5-fold change (FC) (ANOVA P < 0.05). In EAT (shown in red), 383 were upregulated, and 310 were upregulated in SAT (shown in green). (B) Hierarchical 
clustering of differentially expressed genes in control SAT and EAT. (C) KEGG pathway analysis of differentially expressed genes in SAT and EAT.
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Figure 3. Comparison of gene expression between SAT and EAT in cases. (A) Volcano plot of 805 genes that were differentially expressed at a level of 
1.5-fold change (ANOVA P < 0.05). In EAT (red) 427 were upregulated, and 378 were upregulated in SAT (green). (B) Hierarchical clustering of differentially 
expressed genes in SAT and EAT of cases. (C) KEGG pathway analysis of differentially expressed genes in SAT and EAT of cases.
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these differences, we found that expression of  3 members of  the NR4A subfamily of  orphan nuclear hor-
mone receptors was increased in the EAT of  patients without CAD. This has not been previously reported 
to our knowledge and is very interesting considering that members of  this family have been shown to be 
protective in mouse models of  atherosclerosis (17, 18).
The NR4A subfamily of  orphan nuclear hormone receptors belong to the same class of  transcription 
factors as peroxisome proliferator–activated receptor γ. Their protein structure is similar to other mem-
bers in this class, having separate DNA- and ligand-binding domains. They are called “orphan” receptors 
because their endogenous ligands have yet to be discovered. NR4A family members are expressed in a 
broad array of  tissues and have been shown to protect against the initiation and progression of  atheroscle-
rosis (23, 24). Recent studies have highlighted NR4A1 as a key transcriptional regulator of  lipid homeosta-
sis, vascular remodeling, and inflammation (25). NR4A1 has at least 3 important antiinflammatory effects 
relevant to CAD. First, NR4A1 activity is required for the differentiation of  Ly6c– monocytes that patrol 
the endothelium and maintain blood vessel integrity. Nr4a1-null mice lack this antiinflammatory monocyte 
population and display an exaggerated inflammatory response (16, 17). Second, within Ly6c+ monocytes, 
Nr4a1 feeds back to inhibit inflammasome activity and transactivation of  NF-κB by IL-2. Third, Nr4a1 
suppresses induction of  macrophage chemotactic protein-1 expression in response to lipopolysaccharide 
(22). Although we do not know the specific cell type responsible for NR4A1 expression in EAT, we hypoth-
esize that it is macrophages. Hirata et al. reported that the ratio of  M2 (alternatively activated) to M1 
(classically activated) macrophages is greater in the EAT of  patients without CAD (21). The inflammatory 
Figure 4. Comparison of gene expression in EAT between cases and controls. (A) Volcano plot of 326 genes that were differentially expressed at a level 
of 1.5-fold change (ANOVA P < 0.05). Three hundred twelve were upregulated in the EAT of control patients (red) and 14 in the EAT of cases (green). (B) 
Hierarchical clustering of differentially expressed genes in EAT of cases and controls. (C) KEGG pathway analysis of differentially expressed genes in EAT of 
controls. No pathways were significantly enriched in the EAT of cases.
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phase of  myocardial infarction (MI) is characterized by influx of  Ly6chiCCR2hi monocytes (27). The tran-
sition to the reparative phase of  MI is dependent upon NR4A1 downregulation of  inflammatory cytokine 
production and transition to Ly6cloCCR2lo macrophages. Deletion of  NR4A in this context leads to exces-
sive inflammation and maladaptive post-MI remodeling (27). Therefore, we hypothesize that within the 
EAT of  patients without CAD, there exists a greater population of  antiinflammatory macrophages. Deter-
mining whether this is true will require further research.
We showed that epicardial adipocytes are smaller than subcutaneous adipocytes, which is consistent 
with their visceral lineage. This confirms work by prior authors (28). We did not, however, see a difference 
in the size of  epicardial adipocytes between cases and controls; this is in contrast to the work of  Vianello 
et al., who demonstrated that epicardial adipocyte size was greater in patients with CAD than in those 
without (29). We hypothesize that this could be due to differences in the patient population. Vianello et al. 
included only male patients in their study, and the average BMI of  patients in their study was lower (29).
A potentially novel finding in our study is that EAT appears to have a greater number of  blood vessels 
than SAT. This has not been previously shown. This was unexpected because visceral adipose depots have 
previously been demonstrated to have a lower blood vessel density than SAT (30). However, it may be that 
EAT is different from abdominal VAT in this regard. Furthermore, EAT is known to have a blood supply 
from the underlying coronary arteries; therefore it follows that there may be a higher vascularity in this 
adipose depot, which is in close proximity to the heart (8).
Figure 5. Comparison of gene expression in SAT between cases and controls. (A) Volcano plot of 218 genes that were differentially expressed at a level 
of 1.5-fold change (ANOVA P < 0.05). Eighty-two were upregulated in the SAT of control patients (red) and 136 in the SAT of cases (green). (B) Hierarchical 
clustering of differentially expressed genes in SAT of cases and controls. (C) KEGG pathway analysis of differentially expressed genes in SAT of cases. No 
pathways were significantly enriched in the SAT of controls.
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.124859
R E S E A R C H  A R T I C L E
Interestingly, we found that the expression level of  MIR126 was higher in the EAT of  both cases and 
controls compared with SAT. MIR126 is one of  the most abundant MIRs in endothelial cells (31). MIR126 
promotes regeneration of  endothelial cells and regulates endothelial cell turnover (32). The increased 
expression of  this MIR in EAT is consistent with the increased number of  endothelial cells in this depot.
Our study has several limitations. First, we have a modest number of  patients. Second, we could not 
obtain samples of  visceral fat to compare the 3 depots. Third, samples of  EAT were obtained proximal to 
the right coronary artery only, because this is the easiest area for the surgeon to take the biopsy from. These 
limitations aside, we feel that we have made some potentially novel observations regarding the characteris-
tics of  EAT that add to the present literature.
Conclusions. We conclude that the adipose depot, rather that disease status, is the predominant deter-
minant of  gene expression in EAT. EAT has greater inflammatory gene expression than SAT even in the 
absence of  coronary disease; this is consistent with its visceral origin. Regarding disease-specific gene 
expression, patients without coronary disease had higher expression of  all 3 members of  the orphan nucle-
ar hormone receptor family in EAT. This is consistent with mouse studies demonstrating a protective and 
antiinflammatory effect of  these nuclear receptors in atherosclerosis. We hypothesize that these receptors 
may play an important role in limiting adipose tissue inflammation in cardiometabolic disorders.
Methods
Subject recruitment. Adult patients referred for elective cardiac surgery were screened for enrollment and 
informed consent was provided. This study was approved by the UMass IRB (docket H-14436). Patients with 
active infection or cancer were excluded. All patients had preoperative coronary angiography. Control patients 
were referred for elective valve surgery and had no significant CAD (any single lesion >50%) on preoperative 
coronary angiograms. Only 3 controls had single lesions of  30%; otherwise, all had normal coronary arteries 
or minor luminal irregularities. Cases were patients referred for coronary artery bypass surgery because of  
significant CAD. The severity of  CAD was determined by single-blinded review of coronary angiograms and 
calculation of  the Gensini score as previously described (33). The Gensini score is a continuous variable that 
increases with the severity of  coronary atherosclerosis (e.g., a score of  0 = none, and 100 = severe).
Table 2. Differential microRNA expression in SAT and EAT of controls
ID Control
EAT avg (log2)
Control 
SAT avg (log2)
FC ANOVA 
P value
Gene 
Symbol
Description
8159371 5.19 4.41 1.72 0.0005 MIR126 microRNA 126
7981326 8.07 7.38 1.61 5.81E-10 MIR1247 microRNA 1247
8034694 6.07 6.68 –1.53 0.0239 MIR24-2 microRNA 24-2
MIR, microRNA.
Table 3. Differential microRNA expression in SAT and EAT of cases
ID Control EAT 
avg (log2)
Control SAT 
avg (log2)
FC ANOVA P value Gene Symbol Description
7981326 8.08 7.26 1.76 1.78E-09 MIR1247 microRNA 1247
8159371 5.28 4.67 1.52 0.0072 MIR126 microRNA 126
8067944 6.27 5.67 1.52 0.0011 MIRLET7C microRNA let-7c
8011193 8.44 9.02 –1.5 9.73E-08 MIR22 microRNA 22
8034698 7.48 8.18 –1.62 0.0012 MIR23A microRNA 23a
8054611 8.43 9.17 –1.68 5.05E-06 MIR4435 microRNA 4435
8172266 6.2 7.17 –1.96 1.15E-05 MIR221 microRNA 221
8008885 7.65 9.29 –3.12 4.47E-05 MIR21 microRNA 21
8034694 5.27 7.57 –4.94 9.98E-05 MIR24-2 microRNA 24-2
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Figure 6. qRT-PCR verifies downregulation of NR4A1, NR4A2, and NR4A3 in EAT of cases. (A) INTLN1 
expression was greater in EAT than SAT in both cases and controls. (B) NNAT expression was greater in 
SAT than EAT in both cases and controls. (C) NR4A1 expression was significantly decreased in EAT of 
cases compared with controls. (D) NR4A2 expression was reduced in EAT of cases in comparison with all 
other depots. (E) NR4A3 expression was reduced in EAT of cases in comparison with SAT of cases and 
EAT of controls. (F) SOCS3 expression was increased in the SAT of cases compared with other groups. (G) 
PTGS2 expression was increased in the SAT of cases compared with EAT. (H) CCR2 expression was not dif-
ferent between groups. (I) CCL2 expression was not different between groups. (J) IL8 expression was not 
different between groups. (K) IL6 expression was not different between groups. (L) PAI1 expression was 
not different between groups. (M) TNFA expression was not different between groups (n = 11–12 per group; 
**P < 0.01, and *P < 0.05 for indicated comparisons using 2-way ANOVA and Tukey’s multiple-compar-
isons test). In each column, individual subjects are plotted, and error bars show the mean and standard 
deviation per group. White circles represent controls; black squares represent cases.
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Figure 7. Staining of EAT for classical and alternative macrophage markers shows no difference between cases and controls. (A) Staining of EAT for the 
classical macrophage marker CD11c showed no difference between cases and controls. EAT of both cases and controls had more CD11c+ cells than SAT. *P < 
0.05; ***P < 0.001 vs. EAT for indicated comparisons using Kruskal-Wallis test with Dunn’s multiple-comparisons test. In each column, individual subjects 
are plotted, and error bars show the mean and standard deviation per group. (B) Representative CD11c staining in cases and controls. (C) Staining of EAT 
for the alternative macrophage marker MRC1 showed no difference between cases and controls. EAT of both cases and controls had a greater number of 
MRC1+ cells than SAT. ***P < 0.001 vs. EAT for indicated comparisons using Kruskal-Wallis test with Dunn’s multiple-comparisons test. In each column, 
individual subjects are plotted, and error bars show the mean and standard deviation per group. (D) Representative MRC1 staining in cases and controls. 
(E) The average values or CD11c and MRC1+ cells per subject and tissue were divided to create a ratio. There was no difference in the ratio per tissue or group 
using Kruskal-Wallis test.
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Sample collection and preparation. During surgery a sample of  EAT (0.5 g) adjacent to the right coronary 
artery was obtained, a section was taken and stored in 10% formalin, and the remainder was immediately 
snap-frozen in liquid nitrogen (–80°C). Next, a sample of  SAT (0.5 mg) from thoracic subcutaneous fat was 
obtained, a section was taken and stored in 10% formalin, and the remainder was immediately snap-frozen 
in liquid nitrogen (–80°C).
Microarray analysis. RNA was prepared from aliquots of  frozen fat samples using the QIAGEN mini 
lipid RNA extraction kit. RNA quality was analyzed on an Agilent Bioanalyzer. Samples with an RNA 
integrity number below 7.5 were excluded. Samples that passed quality control analysis were sent to the 
UMass Genomics Core for cRNA preparation and hybridization to Affymetrix Human Gene 1.0 Arrays. 
Expression analysis was performed using Affymetrix Transcriptome Analysis Software. The raw data were 
deposited into the National Center for Biotechnology Information’s Gene Expression Omnibus database 
with accession number GSE120774 (http://www.ncbi.nlm.nih.gov/geo).
qRT-PCR. qRT-PCR was performed using a cDNA synthesis kit, SYBR Green Master Mix, and a 
CFX 96 thermocycler (all from Bio-Rad) as previously described (34). Primer sequences were obtained 
from PrimerBank (http://pga.mgh.harvard.edu/primerbank) and were as follows: CCR2 forward CCA-
CATCTCGTTCTCGGTTTATC, CCR2 reverse CAGGGAGCACCGTAATCATAATC, CCL2 forward 
CAGCCAGATGCAATCAATGCC, CCL2 reverse TGGAATCCTGAACCCACTTCT, GAPDH forward 
GGAGCGAGATCCCTCCAAAAT, GAPDH reverse GGCTGTTGTCATACTTCTCATGG, IL8 for-
ward TTTTGCCAAGGAGTGCTAAAGA, IL8 reverse AACCCTCTGCACCCAGTTTTC, IL6 forward 
ACTCACCTCTTCAGAACGAATTG, IL6 reverse CCATCTTTGGAAGGTTCAGGTTG, ITLN1 for-
ward ACGTGCCCAATAAGTCCCC, ITLN1 reverse CCGTTGTCAGTCCAACACTTTC, NNAT for-
ward ACTGGGTAGGATTCGCTTTTCG, NNAT reverse ACACCTCACTTCTCGCAATGG, NR4A1 
forward ATGCCCTGTATCCAAGCCC, NR4A1 reverse GTGTAGCCGTCCATGAAGGT, NR4A2 for-
ward GTTCAGGCGCAGTATGGGTC, NR4A2 reverse CTCCCGAAGAGTGGTAACTGT, NR4A3 
forward TGCGTCCAAGCCCAATATAGC, NR4A3 reverse GGTGTATTCCGAGCTGTATGTCT, PAI1 
forward ACCGCAACGTGGTTTTCTCA, PAI1 reverse TTGAATCCCATAGCTGCTTGAAT, PTGS2 
forward CTGGCGCTCAGCCATACAG, PTGS2 reverse CGCACTTATACTGGTCAAATCCC, SOCS3 
forward CCTGCGCCTCAAGACCTT, SOCS3 reverse GTCACTGCGCTCCAGTAGAA, TNFA forward 
CCTCTCTCTAATCAGCCCTCTG, and TNFA reverse GAGGACCTGGGAGTAGATGAG. Expression 
relative to GAPDH was determined using the ΔΔCt method of  Livak and Schmittgen (35).
Histology and immunohistochemistry. Formalin-fixed sections were embedded in paraffin and sectioned by 
the UMass Diabetes and Endocrinology Research Center (DERC) Morphology Core. Adipocyte size was 
determined on H&E-stained sections using the program Adiposoft as previously described (36). To quantify 
blood vessels, unstained sections were incubated with rabbit anti–human von Willebrand factor (1:300 dilu-
tion) (Abcam ab6994) and then a goat antirabbit secondary antibody conjugated to horseradish peroxidase 
(Pierce 31460). Negative controls using secondary antibody alone were also included. To quantify M1 or M2 
macrophages, cryosections were stained with rabbit anti–human CD11c (1:1000 dilution) (abcam ab52632) 
and rabbit anti–human MRC1 (1:1000 dilution) (abcam ab64693) antibodies and then a goat antirabbit sec-
ondary antibody conjugated to horseradish peroxidase. Three representative fields at original magnification 
×20 of  SAT and EAT of each patient were used to quantify CD11c+ and MRC1+ cells.
Statistics. Clinical characteristics were compared with the 2-tailed Student’s t test for continuous vari-
ables or the χ2 test for dichotomous variables. A P value less than 0.05 was considered significant. Adi-
pocyte size and endothelial cell numbers were compared with 2-tailed Student’s t test. For the qRT-PCR 
experiment, expression values relative to GAPDH were compared using 2-way ANOVA and Tukey’s mul-
tiple-comparisons test. The Affymetrix Transcriptome Analysis Console was used to analyze microarrays 
using 1-way ANOVA and multiple-comparisons testing.
Study approval. This study was reviewed and approved by the UMass Medical Institutional Review Board 
(docket H-14436). All studies were conducted according to the principles expressed in the Declaration of  
Helsinki. Signed informed consent documents were obtained from each participant included in the study.
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